Quanterix Appoints Everett Cunningham as New CEO

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jan 08 2026

0mins

Should l Buy QTRX?

Quanterix Corporation announced that its Board of Directors has appointed Everett Cunningham as the company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Cunningham assumes the role on January 19, 2026. Following Cunningham's start date, Toloue will remain available to the company in an advisory capacity to support continuity and help ensure a smooth leadership transition. Contemporaneous with Cunningham's appointment, Bill Donnelly, Executive Chair of the Board, will transition to his prior role as non-executive Chair of the Board. "We are excited to welcome Everett to Quanterix," said Bill Donnelly, Executive Chair of the Board. "Throughout his career, Everett has demonstrated his ability to accelerate growth at both research tools and diagnostics companies, build high-performing commercial organizations and lead transformational change at scale. His deep understanding of our customers and markets and his track record of operational execution makes him exceptionally well suited to lead Quanterix in its next phase of growth."

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QTRX?" and start using high-conviction signals backed by rigorous historical data.

QTRX

$6.32+Infinity%1D

Analyst Views on QTRX

Wall Street analysts forecast QTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

0 Buy

2 Hold

0 Sell

Hold

Current: 6.450

Low

7.00

Averages

7.50

High

8.00

Current: 6.450

Low

7.00

Averages

7.50

High

8.00

Canaccord

Hold

maintain

$5 -> $8

2025-12-22

Reason

Canaccord

Price Target

$5 -> $8

AI Analysis

2025-12-22

maintain

Hold

Reason

Canaccord raised the firm's price target on Quanterix to $8 from $5 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.

Canaccord

Buy -> Hold

downgrade

$12 -> $5

2025-08-11

Reason

Canaccord

Price Target

$12 -> $5

2025-08-11

downgrade

Buy -> Hold

Reason

Canaccord downgraded Quanterix to Hold from Buy with a price target of $5, down from $12. following the Q2 miss. The firm cites a lack of near-term visibility and catalysts to move the shares higher for the downgrade. Quanterix's results were impacted by increasing headwinds in biopharma and continued National Institutes of Health funding uncertainty, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QTRX

Unlock Now

About QTRX

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Quanterix Submits Blood Test for Alzheimer's Disease to FDA

1 day agoNewsfilter

Significant Milestone: Quanterix has submitted a 510(k) premarket notification for a multi-analyte algorithmic blood test for Alzheimer's disease, marking a crucial advancement in the company's mission to provide non-invasive, high-performance diagnostic tools for evaluating patients with cognitive symptoms.
Breakthrough Device Designation: The test has received Breakthrough Device Designation from the FDA, aimed at accelerating the development and review process, highlighting its potential in addressing life-threatening or irreversibly debilitating diseases.
Comprehensive Biomarkers: Utilizing Quanterix's Simoa® technology, the test integrates five key analytes—p-Tau 217, Aβ42, Aβ40, GFAP, and NfL—offering a more comprehensive assessment of Alzheimer's biological drivers than single-analyte assays, particularly in the early stages of disease progression.
Clinical Validation Support: The submission is backed by extensive clinical evidence published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, spanning three independent cohorts and over 1,800 symptomatic patients, demonstrating the test's effectiveness and reliability.

Quanterix Publishes Landmark Alzheimer’s Study with C-Index of 0.90

Jan 21 2026Businesswire

Significant Findings: Quanterix's study published in JAMA Network Open demonstrates that a multi-biomarker model achieves a high C-index of 0.90 for clinical risk assessment, significantly enhancing the identification of early symptoms of Alzheimer’s disease.
Cutting-Edge Technology: Utilizing ultra-sensitive Simoa® technology to measure four critical biological axes of Alzheimer’s, the research indicates that the combined use of multiple biomarkers provides a more comprehensive view of clinical risk, advancing early diagnosis of the disease.
Innovative Product Leadership: The launch of LucentAD Complete, based on biomarkers evaluated in the study, aims to provide a comprehensive amyloid risk score for symptomatic individuals, marking Quanterix's leadership in Alzheimer’s diagnostics.
Clinical Application Prospects: The study underscores the importance of identifying potential fast progressors, with Quanterix's multi-analyte approach offering new solutions for clinical trial enrollment and patient care, driving the evolution of personalized medicine.

Rich Sparkle Holdings Signs $39 Million Share Offering Agreement

Jan 09 2026Benzinga

Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.

CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026

Jan 09 2026Benzinga

Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.